US20230277506A1 - Novel preparation containing benzimidazole derivative - Google Patents

Novel preparation containing benzimidazole derivative Download PDF

Info

Publication number
US20230277506A1
US20230277506A1 US18/095,971 US202318095971A US2023277506A1 US 20230277506 A1 US20230277506 A1 US 20230277506A1 US 202318095971 A US202318095971 A US 202318095971A US 2023277506 A1 US2023277506 A1 US 2023277506A1
Authority
US
United States
Prior art keywords
tablet
disintegrant
excipient
formulation
binder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/095,971
Inventor
Hyungsuk LIM
Chun Seon Lyu
Sun Young PARK
Kyungmin SHIN
Da Won Oh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HK Inno N Corp
Original Assignee
HK Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HK Inno N Corp filed Critical HK Inno N Corp
Priority to US18/095,971 priority Critical patent/US20230277506A1/en
Publication of US20230277506A1 publication Critical patent/US20230277506A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Definitions

  • the present invention relates to a formulation for oral administration comprising a benzimidazole derivative or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose.
  • (S)-4((5,7-difluorochroman-4-yl)oxy)-N,N-2-trimethyl-1H-benzo[d]imidazole-6-carboxamide is known to have a use for preventing and treating diseases mediated by an acid pump antagonistic activity, such as gastrointestinal diseases, for example, a gastroesophageal disease, a gastroesophageal reflux disease (GERD), a peptic ulcer, a gastric ucler, a duodenal ulcer, an NSAID-induced ulcer, gastritis, a Helicobacter pylori infection, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, a nonerosive reflux disease (NERD), a visceral pain, purosis, nausea, esophagitis, dysphagia, salivation, an airway lesion or asthma (WO 2007/072146).
  • gastrointestinal diseases for example, a gastroesophageal disease, a gastro
  • the above compound has a problem in that its bioavailability and onset of drug action may become instable due to a phenomenon of decline in dissolution rate with an elapsed time of storage, thus still requiring a more research on solving such problem.
  • the objective of the present invention is to provide a novel formulation comprising a benzimidazole derivative, which is protected from having a phenomenon of decline in dissolution rate and also has an excellent storage stability.
  • the present invention provides a formulation for oral administration comprising a compound of (S)-4((5,7-difluorochroman-4-yl)oxy)-N,N-2-trimethyl-1H-benzo[d]imidazole-6-carboxamide of the following Formula 1 or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose:
  • the above formulation for oral administration can be a tablet.
  • a compound of the above Formula 1 is a novel substance for preventing and treating gastrointestinal diseases and bleeding associated therewith by means of a pharmacological mechanism of a potassium competitive acid blocker (P-CAB).
  • P-CAB potassium competitive acid blocker
  • the compound of the above Formula 1 has difficulty in effectively exerting its drug action because the compound shows a serious phenomenon of decline in dissolution rate with an elapsed time of storage.
  • the present inventors have tried to prepare the compound of the above Formula 1 into various formulations, thus, to our surprise, finding that a formulation, which uses croscarmellose sodium, sodium starch glycolate or low-substituted hydroxypropylcellulose as a disintegrant, is protected from having a phenomenon of decline in dissolution rate and exhibits an excellent storage stability at the same time, such that the compound could be used as a formulation, of which dissolution is stable and storage stability is secured as well.
  • inventive compound of Formula 1 can be combined with specific disintegrants of croscarmellose sodium, sodium starch glycolate or low-substituted hydroxypropylcellulose, such that a storage stability of the inventive compound can be secured just by means of a simple preparation process without an addition of a stabilizer constituent for securing the storage stability of drugs, or without a special preparation process or packing process.
  • inventive compound can be unaffected by packing and storage conditions, and its dissolution can be stable and its storage stability can be secured at pH 4.0, which corresponds to a biological environment in stomach and intestines.
  • a pharmaceutically acceptable salt of the compound of the above Formula 1 can be a pharmaceutically acceptable acid-addition salt.
  • the above acid-addition salt can be selected from the group consisting of acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulfate/sulfate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hybenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulfate, naphthalate, 2-napsylate, nicotinate, nitrate, orotate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stearate,
  • a content of the compound of the above Formula 1 comprised in the inventive formulation as an active component or pharmaceutically acceptable salt thereof can be amount to 10 to 140 mg, particularly 20 to 120 mg, or 10 to 40 wt % with regard to the total weight of the formulation, but is not limited thereto, and can be a conventional one, at which the above compound or the pharmaceutically acceptable salt thereof can exhibit its pharmacological activity.
  • the formulation of the present invention comprises at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose.
  • the above low-substituted hydroxypropylcellulose is formed as a low-substituted hydroxypropyl ether of cellulose, a substitution degree of hydropropoxy group can amount to 5 to 16 mass %.
  • a dissolution rate of a formulation which was prepared by using croscarmellose sodium, sodium starch glycolate or low-substituted hydroxypropylcellulose as a disintegrant
  • the formulation was stable in its dissolution because the formulation exhibited almost no phenomenon of decline in dissolution rate under a condition similar to a biological environment in stomach and intestines, unlike a formulation, which was prepared by using crospovidone or Starch 1500 as a disintegrant (Tables 9 to 11 and FIGS. 1 to 4 ).
  • a content of the above disintegrant can be amount to 1 to 20 wt % with regard to the total weight of the formulation. If the content of the above disintegrant is comprised by less than 1 wt % with regard to the total weight of the formulation, a desired bioavailability rate cannot be obtained due to an excessive delay in disintegration, and if being comprised by more than 20 wt %, a property of the formulation and a quality conformance thereof cannot be secured due to its swelling phenomenon caused by a wetting property of the disintegrant.
  • the formulation according to the present invention can further comprise at least one selected from the group comprising a binder, a filler and a lubricant.
  • binder and “excipient” can be used interchangeably.
  • the formulation of the present invention comprises a binder, particularly wherein the binder can be at least one selected from the group comprising starch, microcrystalline cellulose, colloidal silicon dioxide, mannitol, lactose, polyethylen glycol, polyvinylpyrrolidone co-polymer, hydroxypropylcellulose, gelatin and a mixture thereof, and more particularly wherein it can be at least one selected from hydroxypropylcellulose, polyvinylpyrrolidone and copovidone.
  • the binder can be at least one selected from the group comprising starch, microcrystalline cellulose, colloidal silicon dioxide, mannitol, lactose, polyethylen glycol, polyvinylpyrrolidone co-polymer, hydroxypropylcellulose, gelatin and a mixture thereof, and more particularly wherein it can be at least one selected from hydroxypropylcellulose, polyvinylpyrrolidone and copovidone.
  • a content of the above binder can be within a range of 1 to 40 wt % with regard to the total weight of the formulation. If the content of the above binder amounts to less than 1 wt %, it is difficult to prepare a granule having a desired hardness and size due to a lack of agglutination of the formulation. If the content amounts to more than 40 wt %, a desired bioavailability cannot be obtained due to an excessive delay in disintegration.
  • the formulation of the present invention comprises a filler, particularly wherein the filler can be at least one selected from the group comprising lactose, microcrystalline cellulose, mannitol and colloidal silicon dioxide, and more particularly wherein it can be one selected from the group comprising mannitol, microcrystalline cellulose and lactose, but is not limited thereto, and may be one conventionally used in the art.
  • the filler can be at least one selected from the group comprising lactose, microcrystalline cellulose, mannitol and colloidal silicon dioxide, and more particularly wherein it can be one selected from the group comprising mannitol, microcrystalline cellulose and lactose, but is not limited thereto, and may be one conventionally used in the art.
  • a content of the above filler can be one conventionally used in the art, particularly wherein it can be properly chosen within a range of 1 to 99 wt % with regard to the total weight of the formulation.
  • the formulation of the present invention comprises a lubricant, particularly wherein the lubricant can be at least one selected from the group comprising stearic acid, magnesium stearate, calcium stearate, sodium benzoate, sodium stearyl fumarate, glyceryl monooleate, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, zinc stearate and paraffin group, and more particularly wherein it can be magnesium stearate, but is not limited thereto and may be one conventionally used in the art.
  • the lubricant can be at least one selected from the group comprising stearic acid, magnesium stearate, calcium stearate, sodium benzoate, sodium stearyl fumarate, glyceryl monooleate, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, zinc stearate and paraffin group, and more particularly wherein it can be
  • a content of the above lubricant can be one conventionally used in the art, particularly wherein it can be properly chosen within a range of 0.5 to 10 wt % with regard to the total weight of the formulation.
  • the formulation of the present invention can be coated with a film coating agent, wherein the coating agent can be constituted by 0.5 to 10 wt % with regard to the total weight of the formulation.
  • the present invention provides a method for preparing a formulation comprising the compound of the above Formula 1.
  • the formulation can be prepared by means of a known standard technology or a preparation method conventionally used in the art.
  • the method for preparing the inventive formulation can comprise: (a) containing a compound of the above Formula 1 as an active component, combining a disintegrant, at least one diluent and other excipient therewith together, and granulating the resulting mixture by means of a binder solution containing a binder; and (b) drying the above obtained granular substance, adding an excipient, a disintegrant and a lubricant to the mixture substance and mixing them together, and compressing the resulting mixture as a tablet.
  • the present invention provides a pharmaceutical composition comprising a formulation with the compound of the above Formula 1 and the disintegrant.
  • the present invention provides a pharmaceutical composition for preventing or treating gastrointestinal diseases, comprising a formulation with the compound of the above Formula 1 and the disintegrant.
  • the formulation or the pharmaceutical composition of the present invention can comprise the compound of the above Formula 1, thus being used to prevent or treat gastrointestinal diseases mediated by an acid pump antagonistic activity.
  • the present invention provides the use of a formulation comprising a compound of (S)-4((5,7-difluorochroman-4-yl)oxy)-N,N-2-trimethyl-1H-benzo[d]imidazole-6-carboxamide of Formula 1 or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose for oral administration.
  • the present invention provides the use of a formulation comprising a compound of (S)-4((5,7-difluorochroman-4-yl)oxy)-N,N-2-trimethyl-1H-benzo[d]imidazole-6-carboxamide of Formula 1 or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose for manufacture of a medicament for oral administration.
  • a formulation comprising a compound of Formula 1 according to the present invention or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate, and low-substituted hydroxypropylcellulose, exhibits an excellent storage stability and has an effect on preventing a phenomenon of decline in dissolution rate, thus being usefully used as a formulation for oral administration.
  • FIG. 1 illustrates a graph of comparing dissolution rates of a tablet according to Example 1 with each other, respectively under initial and stress conditions, wherein the Example 1 comprises croscarmellose sodium.
  • FIG. 2 illustrates a graph of comparing dissolution rates of a tablet according to Example 12 with each other, respectively under initial and stress conditions, wherein the Example 12 comprises low-substituted hydroxypropylcellulose.
  • FIG. 3 illustrates a graph of comparing dissolution rates of a tablet according to Comparative Example 1 with each other, respectively under initial and stress conditions, wherein the Comparative Example 1 comprises crospovidone.
  • FIG. 4 illustrates a graph of comparing dissolution rates of a tablet according to Comparative Example 2 with each other, respectively under initial and stress conditions, wherein the Comparative Example 2 comprises Starch 1500.
  • a method for preparing a tablet of Example 1 is as follows.
  • a main active ingredient (S)-4((5,7-difluorochroman-4-yl)oxy)-N,N-2-trimethyl-1H-benzo[d]imidazole-6-carboxamide was mixed with mannitol, microcrystalline cellulose and croscarmellose sodium. Then, a binder solution comprising hydroxypropylcellulose and distilled water was added to a mixture resulting from the above mixing process, then a kneading and drying process, and then an sizing was carried out. After that, a substance resulting from the above sizing process was mixed with colloidal silicon dioxide and magnesium stearate, after which a resulting mixture was compressed into and prepared as a tablet. Contents of components comprised in the tablet of the above Example 1 are such as those shown in the following Table 1.
  • Tablets of Examples 2 and 3 were prepared by respectively using lactose and starch instead of mannitol, in comparison with the tablet of Example 1, but, except for that, they were prepared by means of the same method for preparing a tablet as described in the above Example 1. Contents of components comprised in the tablets of the above Examples 2 and 3 are such as those shown in the following Table 1.
  • Tablets of Examples 4 and 5 were prepared by respectively using polyvinylpyrrolidone and copovidone instead of hydroxypropylcellulose, in comparison with the tablet of Example 1, but, except for that, they were prepared by means of the same method for preparing a tablet as described in the above Example 1. Contents of components comprised in the tablets of the above Examples 4 and 5 are such as those shown in the following Table 1.
  • Tablets of Examples 6 to 9 were prepared by varying an amount of croscarmellose sodium, in comparison with the tablet of Example 1, but, except for that, they were prepared by means of the same method for preparing a tablet as described in the above Example 1. Contents of components comprised in the tablets of the above Examples 6 to 9 are such as those shown in the following Table 1.
  • a tablet of Example 10 was prepared by doubling an amount of a main active ingredient, in comparison with the tablet of Example 1, but, except for that, they were prepared by means of the same method for preparing a tablet as described in the above Example 1. Contents of components contained in the tablet of the above Example to are such as those shown in the following Table 1.
  • Tablets of Examples 11 and 12 were prepared by using sodium starch glycolate instead of croscarmellose sodium as a disintegrant in comparison with the tablet of Example 1, but, except for that, they were prepared by means of the same method for preparing a tablet as described in the above Example 1. Contents of components comprised in the tablets of the above Examples 11 and 12 are such as those shown in the following Table 2.
  • Classification Component 11 Main active (S)-4((5,7-difluorochroman-4- 50 50 ingredient yl)oxy)-N,N-2-trimethyl-1H- benzo[d]imidazole-6-carboxamide Excipient Mannitol 50 62 Microcrystalline cellulose 80 58 Colloidal silicon dioxide 2 2 Disintegrant Sodium starch glycolate 10 20 Binder Hydroxypropylcellulose 6 6 Lubricant Magnesium stearate 2 2 Total Weight 200 200
  • a tablet of Example 13 was prepared by using low-substituted hydroxypropylcellulose instead of croscarmellose sodium as a disintegrant in comparison with the tablet of Example 1, but, except for that, they were prepared by means of the same method for preparing a tablet as described in the above Example 1. Contents of components comprised in the tablet of the above Example 13 are such as those shown in the following Table 3.
  • Example 13 (Amount Classification Component Used, mg) Main active (S)-4((5,7-difluorochroman-4-yl)oxy)- 50 ingredient N,N-2-trimethyl-1H-benzo[d]imidazole- 6-carboxamide Excipient Mannitol 50 Microcrystalline cellulose 80 Colloidal silicon dioxide 2 Disintegrant Low-substituted hydroxypropylcellulose 10 Binder Hydroxypropylcellulose 6 Lubricant Magnesium stearate 2 Total Weight 200
  • Example 14 An excipient and a disintegrant, including a main active ingredient, were simply mixed and sized, after which a lubricant was further mixed therewith and a resulting mixture was pressed into a tablet, such that the tablet for oral administration of Example 14 was prepared.
  • Contents of components comprised in the tablet of the above Example 14 are such as those shown in the following Table 4.
  • Example 14 (Amount Classification Component Used, mg) Main active (S)-4((5,7-difluorochroman-4-yl)oxy)- 50 ingredient N,N-2-trimethyl-1H-benzo[d]imidazole- 6-carboxamide Excipient Lactose 84 Silicified microcrystalline cellulose 56 Colloidal silicon dioxide 2 Disintegrant Sodium starch glycolate 6 Lubricant Magnesium stearate 2 Total Weight 200
  • HDPE high-density polyethylene
  • the formulation comprising the compound of Formula 1, which used croscarmellose sodium as a disintegrant, produced almost no impurities, thus identifying that the formulation was excellent in storage stability.
  • a formulation comprising the compound of Formula 1, which used sodium starch glycolate or low-substituted hydroxypropylcellulose as a disintegrant, produced almost no impurities, thus identifying that the formulation was excellent in storage stability.
  • HDPE high-density polyethylene
  • the formulation as prepared by using croscarmellose sodium, sodium starch glycolate or low-substituted hydroxypropylcellulose as a disintegrant, showed almost no phenomenon of decline in dissolution rate at pH 4.0, which is a biological environment in stomach and intestines, when compared to the formulation, as prepared by using crospovidone or Starch 1500 as a disintegrant.

Abstract

The present invention relates to a novel formulation comprising a benzimidazole derivative. The formulation for oral administration comprising a compound of Formula 1 according to the present invention or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose, exhibits an excellent storage stability and has an effect on preventing a phenomenon of decline in dissolution rate, thus being usefully used as a formulation for oral administration.

Description

    TECHNICAL FIELD
  • The present invention relates to a formulation for oral administration comprising a benzimidazole derivative or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose.
    • BACKGROUND ART
  • It is obviously known in the art that even formulations comprising the same active component may show a difference in pharmaceutically important properties such as the solubility, dissolution characteristics and bioavailability of the active component comprised in the formulations depending on an additional constitutional component comprised therein. Thus, in addition to a development of a novel compound, it is also very important to develop a constituent comprised in a formulation so as to maximize a pharmacological effect of the novel, developed compound.
  • Meanwhile, (S)-4((5,7-difluorochroman-4-yl)oxy)-N,N-2-trimethyl-1H-benzo[d]imidazole-6-carboxamide is known to have a use for preventing and treating diseases mediated by an acid pump antagonistic activity, such as gastrointestinal diseases, for example, a gastroesophageal disease, a gastroesophageal reflux disease (GERD), a peptic ulcer, a gastric ucler, a duodenal ulcer, an NSAID-induced ulcer, gastritis, a Helicobacter pylori infection, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, a nonerosive reflux disease (NERD), a visceral pain, purosis, nausea, esophagitis, dysphagia, salivation, an airway lesion or asthma (WO 2007/072146).
  • However, the above compound has a problem in that its bioavailability and onset of drug action may become instable due to a phenomenon of decline in dissolution rate with an elapsed time of storage, thus still requiring a more research on solving such problem.
    • PRIOR ART REFERENCES Patent Document
    • (Patent Document 1) International Patent No. WO 2007/072146
    DISCLOSURE Technical Problem
  • The objective of the present invention is to provide a novel formulation comprising a benzimidazole derivative, which is protected from having a phenomenon of decline in dissolution rate and also has an excellent storage stability.
    • Technical Solution
  • In one aspect for solving the above problem, the present invention provides a formulation for oral administration comprising a compound of (S)-4((5,7-difluorochroman-4-yl)oxy)-N,N-2-trimethyl-1H-benzo[d]imidazole-6-carboxamide of the following Formula 1 or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose:
  • Figure US20230277506A1-20230907-C00001
  • The above formulation for oral administration can be a tablet.
  • In the present invention, a compound of the above Formula 1 is a novel substance for preventing and treating gastrointestinal diseases and bleeding associated therewith by means of a pharmacological mechanism of a potassium competitive acid blocker (P-CAB). The compound of the above Formula 1 has difficulty in effectively exerting its drug action because the compound shows a serious phenomenon of decline in dissolution rate with an elapsed time of storage.
  • Accordingly, the present inventors have tried to prepare the compound of the above Formula 1 into various formulations, thus, to our surprise, finding that a formulation, which uses croscarmellose sodium, sodium starch glycolate or low-substituted hydroxypropylcellulose as a disintegrant, is protected from having a phenomenon of decline in dissolution rate and exhibits an excellent storage stability at the same time, such that the compound could be used as a formulation, of which dissolution is stable and storage stability is secured as well. More particularly, the inventive compound of Formula 1 can be combined with specific disintegrants of croscarmellose sodium, sodium starch glycolate or low-substituted hydroxypropylcellulose, such that a storage stability of the inventive compound can be secured just by means of a simple preparation process without an addition of a stabilizer constituent for securing the storage stability of drugs, or without a special preparation process or packing process. By doing so, the inventive compound can be unaffected by packing and storage conditions, and its dissolution can be stable and its storage stability can be secured at pH 4.0, which corresponds to a biological environment in stomach and intestines.
  • In the present invention, the above “(S)-4((5,7-difluorochroman-4-yl)oxy)-N,N-2-trimethyl-1H-benzo[d]imidazole-6-carboxamide,” which is a type of benzimidazole derivative, exhibits an acid pump inhibitory activity.
  • In the present invention, a pharmaceutically acceptable salt of the compound of the above Formula 1 can be a pharmaceutically acceptable acid-addition salt.
  • Particularly, the above acid-addition salt can be selected from the group consisting of acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulfate/sulfate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hybenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulfate, naphthalate, 2-napsylate, nicotinate, nitrate, orotate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate and xinafoate salts, but is not limited thereto, and a salt, which may conventionally exhibit a pharmacological activity of the compound of the above Formula 1, can be used without a limitation.
  • A content of the compound of the above Formula 1 comprised in the inventive formulation as an active component or pharmaceutically acceptable salt thereof can be amount to 10 to 140 mg, particularly 20 to 120 mg, or 10 to 40 wt % with regard to the total weight of the formulation, but is not limited thereto, and can be a conventional one, at which the above compound or the pharmaceutically acceptable salt thereof can exhibit its pharmacological activity.
  • The formulation of the present invention comprises at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose.
  • In the present invention, the above low-substituted hydroxypropylcellulose is formed as a low-substituted hydroxypropyl ether of cellulose, a substitution degree of hydropropoxy group can amount to 5 to 16 mass %.
  • In one embodiment of the present invention, as a result of identifying a storage stability of a formulation, which was prepared by using croscarmellose sodium, sodium starch glycolate or low-substituted hydroxypropylcellulose as a disintegrant, it could be seen that the formulation was excellent in its storage stability because the formulation produced almost no impurities even after being stored for 7 days under a stress condition (60° C., 80% RH) (Tables 7 and 8).
  • Also, in one embodiment of the present invention, as a result of identifying a dissolution rate of a formulation, which was prepared by using croscarmellose sodium, sodium starch glycolate or low-substituted hydroxypropylcellulose as a disintegrant, it could be seen that the formulation was stable in its dissolution because the formulation exhibited almost no phenomenon of decline in dissolution rate under a condition similar to a biological environment in stomach and intestines, unlike a formulation, which was prepared by using crospovidone or Starch 1500 as a disintegrant (Tables 9 to 11 and FIGS. 1 to 4 ).
  • In the present invention, a content of the above disintegrant can be amount to 1 to 20 wt % with regard to the total weight of the formulation. If the content of the above disintegrant is comprised by less than 1 wt % with regard to the total weight of the formulation, a desired bioavailability rate cannot be obtained due to an excessive delay in disintegration, and if being comprised by more than 20 wt %, a property of the formulation and a quality conformance thereof cannot be secured due to its swelling phenomenon caused by a wetting property of the disintegrant.
  • The formulation according to the present invention can further comprise at least one selected from the group comprising a binder, a filler and a lubricant.
  • In the present invention, the term “binder” and “excipient” can be used interchangeably.
  • The formulation of the present invention comprises a binder, particularly wherein the binder can be at least one selected from the group comprising starch, microcrystalline cellulose, colloidal silicon dioxide, mannitol, lactose, polyethylen glycol, polyvinylpyrrolidone co-polymer, hydroxypropylcellulose, gelatin and a mixture thereof, and more particularly wherein it can be at least one selected from hydroxypropylcellulose, polyvinylpyrrolidone and copovidone.
  • A content of the above binder can be within a range of 1 to 40 wt % with regard to the total weight of the formulation. If the content of the above binder amounts to less than 1 wt %, it is difficult to prepare a granule having a desired hardness and size due to a lack of agglutination of the formulation. If the content amounts to more than 40 wt %, a desired bioavailability cannot be obtained due to an excessive delay in disintegration.
  • The formulation of the present invention comprises a filler, particularly wherein the filler can be at least one selected from the group comprising lactose, microcrystalline cellulose, mannitol and colloidal silicon dioxide, and more particularly wherein it can be one selected from the group comprising mannitol, microcrystalline cellulose and lactose, but is not limited thereto, and may be one conventionally used in the art.
  • A content of the above filler can be one conventionally used in the art, particularly wherein it can be properly chosen within a range of 1 to 99 wt % with regard to the total weight of the formulation.
  • The formulation of the present invention comprises a lubricant, particularly wherein the lubricant can be at least one selected from the group comprising stearic acid, magnesium stearate, calcium stearate, sodium benzoate, sodium stearyl fumarate, glyceryl monooleate, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, zinc stearate and paraffin group, and more particularly wherein it can be magnesium stearate, but is not limited thereto and may be one conventionally used in the art.
  • A content of the above lubricant can be one conventionally used in the art, particularly wherein it can be properly chosen within a range of 0.5 to 10 wt % with regard to the total weight of the formulation.
  • The formulation of the present invention can be coated with a film coating agent, wherein the coating agent can be constituted by 0.5 to 10 wt % with regard to the total weight of the formulation.
  • The present invention provides a method for preparing a formulation comprising the compound of the above Formula 1. The formulation can be prepared by means of a known standard technology or a preparation method conventionally used in the art.
  • Particularly, the method for preparing the inventive formulation can comprise: (a) containing a compound of the above Formula 1 as an active component, combining a disintegrant, at least one diluent and other excipient therewith together, and granulating the resulting mixture by means of a binder solution containing a binder; and (b) drying the above obtained granular substance, adding an excipient, a disintegrant and a lubricant to the mixture substance and mixing them together, and compressing the resulting mixture as a tablet.
  • However, it is not limited to the above preparation method and can be subject to change according to a principle known in the art.
  • The present invention provides a pharmaceutical composition comprising a formulation with the compound of the above Formula 1 and the disintegrant.
  • The present invention provides a pharmaceutical composition for preventing or treating gastrointestinal diseases, comprising a formulation with the compound of the above Formula 1 and the disintegrant.
  • The formulation or the pharmaceutical composition of the present invention can comprise the compound of the above Formula 1, thus being used to prevent or treat gastrointestinal diseases mediated by an acid pump antagonistic activity.
  • In other aspect for solving the above problem, the present invention provides the use of a formulation comprising a compound of (S)-4((5,7-difluorochroman-4-yl)oxy)-N,N-2-trimethyl-1H-benzo[d]imidazole-6-carboxamide of Formula 1 or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose for oral administration.
  • In other aspect for solving the above problem, the present invention provides the use of a formulation comprising a compound of (S)-4((5,7-difluorochroman-4-yl)oxy)-N,N-2-trimethyl-1H-benzo[d]imidazole-6-carboxamide of Formula 1 or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose for manufacture of a medicament for oral administration.
    • Advantageous Effects
  • A formulation comprising a compound of Formula 1 according to the present invention or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate, and low-substituted hydroxypropylcellulose, exhibits an excellent storage stability and has an effect on preventing a phenomenon of decline in dissolution rate, thus being usefully used as a formulation for oral administration.
    • DESCRIPTION OF DRAWINGS
  • FIG. 1 illustrates a graph of comparing dissolution rates of a tablet according to Example 1 with each other, respectively under initial and stress conditions, wherein the Example 1 comprises croscarmellose sodium.
  • FIG. 2 illustrates a graph of comparing dissolution rates of a tablet according to Example 12 with each other, respectively under initial and stress conditions, wherein the Example 12 comprises low-substituted hydroxypropylcellulose.
  • FIG. 3 illustrates a graph of comparing dissolution rates of a tablet according to Comparative Example 1 with each other, respectively under initial and stress conditions, wherein the Comparative Example 1 comprises crospovidone.
  • FIG. 4 illustrates a graph of comparing dissolution rates of a tablet according to Comparative Example 2 with each other, respectively under initial and stress conditions, wherein the Comparative Example 2 comprises Starch 1500.
    •  MODE FOR INVENTION
  • Hereinafter, configuration and effects of the present invention will be described in more detail through preparation examples, examples and experimental examples. However, the following preparation examples, examples and experimental examples are provided only for the purpose of illustrating the present invention, and thus the present invention is not limited thereto.
    • Preparation Example 1: Preparing of a Tablet Containing Croscarmellose Sodium
  • A method for preparing a tablet of Example 1 is as follows.
  • A main active ingredient (S)-4((5,7-difluorochroman-4-yl)oxy)-N,N-2-trimethyl-1H-benzo[d]imidazole-6-carboxamide was mixed with mannitol, microcrystalline cellulose and croscarmellose sodium. Then, a binder solution comprising hydroxypropylcellulose and distilled water was added to a mixture resulting from the above mixing process, then a kneading and drying process, and then an sizing was carried out. After that, a substance resulting from the above sizing process was mixed with colloidal silicon dioxide and magnesium stearate, after which a resulting mixture was compressed into and prepared as a tablet. Contents of components comprised in the tablet of the above Example 1 are such as those shown in the following Table 1.
  • Tablets of Examples 2 and 3 were prepared by respectively using lactose and starch instead of mannitol, in comparison with the tablet of Example 1, but, except for that, they were prepared by means of the same method for preparing a tablet as described in the above Example 1. Contents of components comprised in the tablets of the above Examples 2 and 3 are such as those shown in the following Table 1.
  • Tablets of Examples 4 and 5 were prepared by respectively using polyvinylpyrrolidone and copovidone instead of hydroxypropylcellulose, in comparison with the tablet of Example 1, but, except for that, they were prepared by means of the same method for preparing a tablet as described in the above Example 1. Contents of components comprised in the tablets of the above Examples 4 and 5 are such as those shown in the following Table 1.
  • Tablets of Examples 6 to 9 were prepared by varying an amount of croscarmellose sodium, in comparison with the tablet of Example 1, but, except for that, they were prepared by means of the same method for preparing a tablet as described in the above Example 1. Contents of components comprised in the tablets of the above Examples 6 to 9 are such as those shown in the following Table 1.
  • A tablet of Example 10 was prepared by doubling an amount of a main active ingredient, in comparison with the tablet of Example 1, but, except for that, they were prepared by means of the same method for preparing a tablet as described in the above Example 1. Contents of components contained in the tablet of the above Example to are such as those shown in the following Table 1.
  • TABLE 1
    Example (Amount Used, mg)
    Classification Component 1 2 3 4 5 6 7 8 9 10
    Main active (S)-4((5,7- 50 50 50 50 50 50 50 50 50 100
    ingredient difluorochroman-4-yl)oxy)-
    N,N-2-trimethyl-1H-
    benzo[d]imidazole-6-
    carboxamide
    Excipient Mannitol 50 — — 50 50 54 44 40 30 100
    Lactose — 62 — — — — — — — —
    Starch — — 62 — — — — — — —
    Microcrystalline cellulose 80 68 68 80 80 80 80 80 80 160
    Colloidal silicon dioxide 2  2 2  2 2 2 2 2 2 4
    Disintegrant Croscarmellose sodium 10 10 10 10 10 6 16 20 30 20
    Binder Hydroxypropylcellulose 6  6 6 — — 6 6 6 6 12
    Polyvinylpyrrolidone — — —  6 — — — — — —
    Copovidone — — — — 6 — — — — —
    Lubricant Magnesium stearate 2  2 2  2 2 2 2 2 2 4
    Total Weight 200 200  200 200  200 200 200 200 200 400
    • Preparation Example 2: Preparing of a Tablet Containing Sodium Starch Glycolate
  • Tablets of Examples 11 and 12 were prepared by using sodium starch glycolate instead of croscarmellose sodium as a disintegrant in comparison with the tablet of Example 1, but, except for that, they were prepared by means of the same method for preparing a tablet as described in the above Example 1. Contents of components comprised in the tablets of the above Examples 11 and 12 are such as those shown in the following Table 2.
  • TABLE 2
    Example
    (Amount Used, mg)
    Classification Component 11 12
    Main active (S)-4((5,7-difluorochroman-4- 50 50
    ingredient yl)oxy)-N,N-2-trimethyl-1H-
    benzo[d]imidazole-6-carboxamide
    Excipient Mannitol 50 62
    Microcrystalline cellulose 80 58
    Colloidal silicon dioxide 2 2
    Disintegrant Sodium starch glycolate 10 20
    Binder Hydroxypropylcellulose 6 6
    Lubricant Magnesium stearate 2 2
    Total Weight 200 200
    • Preparation Example 3: Preparing of a Tablet Containing Low-Substituted Hydroxypropylcellulose
  • A tablet of Example 13 was prepared by using low-substituted hydroxypropylcellulose instead of croscarmellose sodium as a disintegrant in comparison with the tablet of Example 1, but, except for that, they were prepared by means of the same method for preparing a tablet as described in the above Example 1. Contents of components comprised in the tablet of the above Example 13 are such as those shown in the following Table 3.
  • TABLE 3
    Example 13
    (Amount
    Classification Component Used, mg)
    Main active (S)-4((5,7-difluorochroman-4-yl)oxy)- 50
    ingredient N,N-2-trimethyl-1H-benzo[d]imidazole-
    6-carboxamide
    Excipient Mannitol 50
    Microcrystalline cellulose 80
    Colloidal silicon dioxide 2
    Disintegrant Low-substituted hydroxypropylcellulose 10
    Binder Hydroxypropylcellulose 6
    Lubricant Magnesium stearate 2
    Total Weight 200
    • Preparation Example 4: Preparing of a Simple Mix Tablet Containing Sodium Starch Glycolate
  • An excipient and a disintegrant, including a main active ingredient, were simply mixed and sized, after which a lubricant was further mixed therewith and a resulting mixture was pressed into a tablet, such that the tablet for oral administration of Example 14 was prepared. Contents of components comprised in the tablet of the above Example 14 are such as those shown in the following Table 4.
  • TABLE 4
    Example 14
    (Amount
    Classification Component Used, mg)
    Main active (S)-4((5,7-difluorochroman-4-yl)oxy)- 50
    ingredient N,N-2-trimethyl-1H-benzo[d]imidazole-
    6-carboxamide
    Excipient Lactose 84
    Silicified microcrystalline cellulose 56
    Colloidal silicon dioxide 2
    Disintegrant Sodium starch glycolate 6
    Lubricant Magnesium stearate 2
    Total Weight 200
    • Preparation Example 5: Preparing of a Tablet Containing Crospovidone
  • A tablet for oral administration of Comparative Example 1, which used crospovidone as a disintegrant, was prepared by means of the same method for preparing a tablet as described in Example 1, with contents of components shown in the following Table 5.
  • TABLE 5
    Comparative
    Example 1
    (Amount
    Classification Component Used, mg)
    Main active (S)-4((5,7-difluorochroman-4-yl)oxy)- 50
    ingredient N,N-2-trimethyl-1H-benzo[d]imidazole-
    6-carboxamide
    Excipient Mannitol 62
    Microcrystalline cellulose 68
    Colloidal silicon dioxide 2
    Binder Hydroxypropylcellulose 6
    Disintegrant Crospovidone
    10
    Lubricant Magnesium stearate 2
    Total Weight 200
    • Preparation example 6: Preparing of a Tablet Containing Starch 1500
  • A tablet for oral administration of Comparative Example 2, which used Starch 1500 as a disintegrant, was prepared by means of the same method for preparing a tablet as described in Example 1, with contents of components shown in the following Table 6.
  • TABLE 6
    Comparative
    Example 1
    (Amount
    Classification Component Used, mg)
    Main active (S)-4((5,7-difluorochroman-4-yl)oxy)- 50
    ingredient N,N-2-trimethyl-1H-benzo[d]imidazole-
    6-carboxamide
    Excipient Mannitol 50
    Microcrystalline cellulose 80
    Colloidal silicon dioxide 2
    Binder Hydroxypropylcellulose 6
    Disintegrant Starch 1500 10
    Lubricant Magnesium stearate 2
    Total Weight 200
    • Experimental Example 1: Storage Stability Test
  • Tablets of Examples 1 to 14, prepared according to the above Preparation Examples 1 to 4, were inserted into each of high-density polyethylene (HDPE) bottles, after which resulting bottles were stored under a stress condition (60° C., 80% RH) for 7 days, such that properties of the tablets were identified and a purity test thereof was carried out as well.
  • (1) Impurity Test Evaluation on Tablet Comprising Croscarmellose Sodium
  • Particularly, as a result of carrying out an evaluation on the occurrence or increase of impurities after the storage of the tablets of Examples 1 to 10, as prepared by using croscarmellose sodium as a disintegrant, no pattern of occurrence or increase of impurities was identified in all the tablets of Examples 1 to 10 (Table 7).
  • TABLE 7
    Example
    Component (%) 1 2 3 4 5 9 10
    Initial Content (API) 99.94 99.94 99.81 99.94 99.79 99.93 100.00
    Condition Total impurities 0.06 0.06 0.19 0.06 0.21 0.07 0.00
    Stress Condition Content (API) 99.94 99.94 99.80 99.94 99.81 99.93 99.98
    Storage for Total impurities 0.06 0.06 0.2 0.06 0.19 0.07 0.02
    7 Days
  • Accordingly, the formulation comprising the compound of Formula 1, which used croscarmellose sodium as a disintegrant, produced almost no impurities, thus identifying that the formulation was excellent in storage stability.
  • (2) Purity Test Evaluation on Tablet Comprising Sodium Starch Glycolate or Low-Substituted Hydroxypropylcellulose
  • Particularly, as a result of carrying out an evaluation on a production or increase of impurities after the storage of the tablets of Examples 11 to 12, as prepared by using sodium starch glycolate as a disintegrant, as well as the tablet of Example 13, as prepared by using low-substituted hydroxypropylcellulose as a disintegrant, it was identified that no pattern of occurrence or increase of impurities was identified in all the tablets of the Examples 11 to 13 (Table 8).
  • TABLE 8
    Example
    Component (%) 11 13
    Initial Condition Content (API) 99.84 99.94
    Total impurities 0.16 0.06
    Stress Condition Content (API) 99.83 99.93
    Storage for 7 Days Total impurities 0.17 0.07
  • Accordingly, a formulation comprising the compound of Formula 1, which used sodium starch glycolate or low-substituted hydroxypropylcellulose as a disintegrant, produced almost no impurities, thus identifying that the formulation was excellent in storage stability.
    • Experimental Example 2: Dissolution Stability Test
  • Tablets of Examples 1 to 14, prepared according to the above Preparation Examples 1 to 4, were inserted into each of high-density polyethylene (HDPE) bottles, after which resulting bottles were stored under a stress condition (60° C., 80% RH) for 7 days, such that an in vitro dissolution test and an HPLC analysis were carried out.
  • (1) Evaluation on Dissolution Rate of Tablet Comprising Croscarmellose Sodium
  • Particularly, a dissolution experiment was carried out on tablets of Examples 1 to 10, as prepared by using croscarmellose sodium as a disintegrant, wherein conditions for the dissolution experiment were such as those described below:
      • 1.) Basis of dissolution test: Dissolution test method in general test methods in the 11th Revision of the Korean Pharmacopoeia
      • 2) Dissolution test method: Dissolution test method II, paddle method
      • 3) Dissolution test solution: 900 ml of pH 4.0 acetate buffer solution
      • 4) Temperature condition: Maintained at 37.2° C.±0.5° C.
      • 5) Analysis method: HPLC method
      • Detector: Ultraviolet absorptiometer (measurement wavelength: 262 nm)
      • Column: C18 5 um/4.6×150 mm column
      • Mobile phase: Acetonitrile: Distilled water [gradient]
  • As a result of comparing dissolution rates with each other at a time of 15 minutes after onset of dissolution, it was found that the dissolution rates fall within the specified criteria, and it was identified that there occurred no phenomenon of decline in dissolution rate in all the tablets of the Examples 1 to 10 (Table 9 and FIG. 1 ).
  • TABLE 9
    Time Example
    (15 Minutes) 1 2 3 4 5 6 7 8 9 10
    Dissolution Rate 85.0 80.6 80.7 86.5 81.5 85.0 88.8 86.0 81.9 77.1
    (%) under
    Initial Condition
    Dissolution Rate 85.7 78.1 75.5 84.0 85.1 81.3 89.4 84.2 82.0 76.6
    (%) under
    Stress Condition
    (7 days in storage)
  • (2) Evaluation on Dissolution Rate of Tablet Comprising Sodium Starch Glycolate or Low-Substituted Hydroxypropylcellulose
  • Particularly, a dissolution experiment was carried out on tablets of Examples 11, 12 and 14, as prepared by using sodium starch glycolate as a disintegrant, as well as a tablet of Example 13, as prepared by using low-substituted hydroxypropylcellulose as a disintegrant, wherein conditions for the dissolution experiment were such as those described below:
      • 1) Basis of dissolution test: Dissolution test method in general test methods in the 11th Revision of the Korean Pharmacopoeia
      • 2) Dissolution test method: Dissolution test method II, paddle method
      • 3) Dissolution test solution: 900 ml of pH 4.0 acetate buffer solution
      • 4) Temperature condition: Maintained at 37.2° C.±0.5° C.
      • 5) Analysis method: HPLC method
        • Detector: Ultraviolet absorptiometer (measurement wavelength: 262 nm)
        • Column: C18 5 um/4.6×150 mm column
        • Mobile phase: Acetonitrile: Distilled water [gradient]
  • As a result of comparing dissolution rates with each other at a time of 15 minutes after onset of dissolution, it was found that the dissolution rates fall within the specified criteria, it was identified that there occurred no phenomenon of decline in dissolution rate in all the tablets of the Examples 11 to 14 (Table 10 and FIG. 2 ).
  • TABLE 10
    Example
    Time (15 Minutes) 11 12 13 14
    Dissolution Rate (%) under Initial 85.5 84.8 76.8 81.1
    Condition
    Dissolution Rate (%) under Stress 82.3 84.7 75.3 79.6
    Condition (7 days in storage)
  • (3) Evaluation on Dissolution Rate of Tablet Comprising Crospovidone or Starch 1500
  • Particularly, a dissolution experiment was carried out on tablets of Comparative Examples 1 and 2, as prepared by using crospovidone or Starch 1500 as a disintegrant, wherein conditions for the dissolution experiment were such as those described below:
      • 1) Basis of dissolution test: Dissolution test method out of general test methods in the 11th Revision of the Korean Pharmacopoeia
      • 2) Dissolution test method: Dissolution test method II, paddle method
      • 3) Dissolution test solution: 900 ml of pH 4.0 acetate buffer solution
      • 4) Temperature condition: Maintained at 37.2° C.±0.5° C.
      • 5) Analysis method: HPLC method
        • Detector: Ultraviolet absorptiometer (measurement wavelength: 262 nm)
        • Column: C18 5 um/4.6×150 mm column
        • Mobile phase: Acetonitrile: Distilled water [gradient]
  • As a result of comparing dissolution rates with each other at a time of 15 minutes after onset of dissolution, it was identified that there occurred a phenomenon of decline in dissolution rate after storage in the stress condition in comparison with the initial condition (Table 11 and FIGS. 3 and 4 ).
  • TABLE 11
    Comparative Example
    Time (15 Minutes) 1 2
    Dissolution Rate (%) under Initial 85.2 61.7
    Condition
    Dissolution Rate (%) under Stress 68.6 40.3
    Condition (7 days in storage)
  • According to the Experimental Example 2 above, it was identified that the formulation, as prepared by using croscarmellose sodium, sodium starch glycolate or low-substituted hydroxypropylcellulose as a disintegrant, showed almost no phenomenon of decline in dissolution rate at pH 4.0, which is a biological environment in stomach and intestines, when compared to the formulation, as prepared by using crospovidone or Starch 1500 as a disintegrant.
  • While certain portions of the present invention have been described in detail above, such specific descriptions are set forth only to illustrate preferred exemplary embodiments, so it is obvious to those skilled in the art that the scope of the present invention is not limited thereto.
  • Therefore, the actual scope of the present invention will be defined by the accompanying claims and equivalents thereto.

Claims (21)

1.-9. (canceled)
10. A tablet comprising a compound of Formula 1, or a pharmaceutically acceptable salt thereof, prepared by a process comprising:
mixing the compound with an excipient and a disintegrant;
adding a binder solution comprising at least one binder and distilled water, thereby creating a mixture;
kneading and drying the mixture;
adding a lubricant to the mixture; and
pressing the mixture into a tablet
Figure US20230277506A1-20230907-C00002
11. The tablet of claim 10, wherein the excipient is mannitol, lactose, starch, microcrystalline cellulose, colloidal silicon dioxide, or a combination thereof.
12. The tablet of claim 11, wherein the excipient is a combination of mannitol and microcrystalline cellulose.
13. The tablet of claim 11, wherein the excipient is a combination of lactose and microcrystalline cellulose.
14. The tablet of claim 11, wherein the excipient is a combination of starch and microcrystalline cellulose.
15. The tablet of claim 10, wherein the disintegrant is croscarmellose sodium, sodium starch glycolate, or low-substituted hydroxypropylcellulose.
16. The tablet of claim 15, wherein the disintegrant is croscarmellose sodium.
17. The tablet of claim 16, wherein the croscarmellose sodium ranges from 6 mg to 30 mg and the tablet has a mass of 200 mg.
18. The tablet of claim 15, wherein the disintegrant is sodium starch glycolate.
19. The tablet of claim 15, wherein the disintegrant is low-substituted hydroxypropylcellulose having a substitution degree of a hydroxypropoxy group that amounts to 5 to 16 mass %.
20. The tablet of claim 10, wherein the binder is hydroxypropylcellulose, polyvinylpyrrolidone, or copovidone.
21. The tablet of claim 20, wherein the binder is hydroxypropylcellulose.
22. The tablet of claim 20, wherein the binder is polyvinylpyrrolidone.
23. The tablet of claim 20, wherein the binder is copovidone.
24. The tablet of claim 10, wherein the lubricant is at least one selected from the group consisting of stearic acid, magnesium stearate, calcium stearate, sodium benzoate, sodium stearyl fumarate, glyceryl monooleate, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, zinc stearate, paraffin group, and mixtures thereof.
25. The tablet of claim 24, wherein the lubricant is magnesium stearate.
26. The tablet of claim 10, wherein the process for preparing further comprises sizing the mixture to obtain granules of a certain size.
27. The tablet of claim 10, further comprising adding a second excipient when adding the lubricant.
28. The tablet of claim 27, wherein the second excipient is colloidal silicon dioxide.
29. The tablet of claim 10, wherein the compound is in the amount of 50 mg or 100 mg.
US18/095,971 2016-12-26 2023-01-11 Novel preparation containing benzimidazole derivative Pending US20230277506A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/095,971 US20230277506A1 (en) 2016-12-26 2023-01-11 Novel preparation containing benzimidazole derivative

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR1020160179334A KR101960357B1 (en) 2016-12-26 2016-12-26 The novel formulation comprising a benzimidazole derivative
KR10-2016-0179334 2016-12-26
PCT/KR2017/015489 WO2018124700A1 (en) 2016-12-26 2017-12-26 Novel preparation containing benzimidazole derivative
US201916473748A 2019-06-26 2019-06-26
US18/095,971 US20230277506A1 (en) 2016-12-26 2023-01-11 Novel preparation containing benzimidazole derivative

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2017/015489 Continuation WO2018124700A1 (en) 2016-12-26 2017-12-26 Novel preparation containing benzimidazole derivative
US16/473,748 Continuation US11576898B2 (en) 2016-12-26 2017-12-26 Preparation containing benzimidazole derivative

Publications (1)

Publication Number Publication Date
US20230277506A1 true US20230277506A1 (en) 2023-09-07

Family

ID=62710016

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/473,748 Active 2038-08-14 US11576898B2 (en) 2016-12-26 2017-12-26 Preparation containing benzimidazole derivative
US18/095,971 Pending US20230277506A1 (en) 2016-12-26 2023-01-11 Novel preparation containing benzimidazole derivative

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/473,748 Active 2038-08-14 US11576898B2 (en) 2016-12-26 2017-12-26 Preparation containing benzimidazole derivative

Country Status (15)

Country Link
US (2) US11576898B2 (en)
EP (1) EP3560482B9 (en)
JP (1) JP6814886B2 (en)
KR (1) KR101960357B1 (en)
CN (2) CN110121333B (en)
AR (1) AR110453A1 (en)
BR (1) BR112019013098A2 (en)
ES (1) ES2887020T3 (en)
JO (1) JOP20170197B1 (en)
MX (1) MX2019007239A (en)
MY (1) MY191261A (en)
PH (1) PH12019501288A1 (en)
TW (1) TWI658841B (en)
UY (1) UY37550A (en)
WO (1) WO2018124700A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020225520A1 (en) * 2019-02-18 2021-10-14 Hk Inno.N Corporation Pharmaceutical composition comprising benzimidazole derivative compound
BR112022020755A2 (en) * 2020-04-13 2022-12-20 Hk Inno N Corp USE OF A PHARMACEUTICAL COMPOSITION
KR20220054211A (en) * 2020-10-23 2022-05-02 에이치케이이노엔 주식회사 Orally Disintegrating Tablet Comprising Benzimidazole Derivative Compound and Preparation Method Thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0620081B8 (en) 2005-12-19 2021-05-25 Pfizer compound and pharmaceutical composition.
AU2007266574A1 (en) 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US9034860B2 (en) 2006-12-07 2015-05-19 Daiichi Sankyo Company, Limited Pharmaceutical composition containing low-substituted hydroxypropyl cellulose
DK3305291T3 (en) * 2015-06-08 2021-06-28 Hk Inno N Corp Uses of benzimidazole derivative for nocturnal acid breakthrough

Also Published As

Publication number Publication date
MX2019007239A (en) 2019-08-16
TWI658841B (en) 2019-05-11
US20200392120A1 (en) 2020-12-17
TW201828928A (en) 2018-08-16
JOP20170197A1 (en) 2019-01-30
CN110121333A (en) 2019-08-13
UY37550A (en) 2018-07-31
CN110121333B (en) 2023-07-04
WO2018124700A1 (en) 2018-07-05
ES2887020T3 (en) 2021-12-21
BR112019013098A2 (en) 2019-12-17
JP6814886B2 (en) 2021-01-20
AR110453A1 (en) 2019-03-27
EP3560482B1 (en) 2021-08-18
JP2020502208A (en) 2020-01-23
JOP20170197B1 (en) 2022-03-14
EP3560482B9 (en) 2022-04-20
EP3560482A1 (en) 2019-10-30
PH12019501288A1 (en) 2019-12-02
CN116869915A (en) 2023-10-13
MY191261A (en) 2022-06-12
US11576898B2 (en) 2023-02-14
KR20180075235A (en) 2018-07-04
KR101960357B1 (en) 2019-03-20
EP3560482A4 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
US20230277506A1 (en) Novel preparation containing benzimidazole derivative
US9931406B2 (en) Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant
US20220062263A1 (en) Crystalline forms and processes of lenvatinib besylate
TW201717937A (en) Pharmaceutical composition containing aryl alkyl amine compound
US10583087B2 (en) Pharmaceutical composition for oral administration
JP6737060B2 (en) Method for producing pharmaceutical composition containing irbesartan
EP3860606B1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
US9750700B2 (en) Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
US20130085145A1 (en) Imatinib mesilate pharmaceutical tablet
US20240122857A1 (en) Pharmaceutical formulations of indoleamine 2, 3-dioxygenase inhibitors
US20230255967A1 (en) Pharmaceutical compositions comprising a diaminopyrimidine derivative or pharmaceutically acceptable salt thereof and processes for preparing the same
US10688050B1 (en) Pharmaceutical composition comprising ibrutinib
EP4260848A1 (en) Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
JP6455293B2 (en) Formulation containing sertraline and / or a pharmaceutically acceptable salt thereof
JP2020111545A (en) Azilsartan-containing composition
WO2022162687A1 (en) Pharmaceutical compositions comprising nilotinib
TR2021017729A2 (en) A FILM-COATED TABLET CONTAINING MICRONIZED TOFACITINIB
US20190038564A1 (en) Carvedilol Immediate Release Formulation Having Improved Madescent
JP2022139865A (en) tablet
JP2020094025A (en) Solid preparations containing azilsartan and amlodipine besilate and methods for producing solid formulations
US20120289517A1 (en) Solid pharmaceutical composition for oral administration
WO2013139826A1 (en) Pharmaceutical compositions comprising imatinib

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION